# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Eli Lilly is up a remarkable 97.38% over the past year and 55.32% year-to-date. Strong technical indicators suggest continued m...
Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the wo...
Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs...
Active fund managers making large bets on momentum plays indicate confidence that Big Tech's rally has legs for the remaind...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, ra...